ZYKADIA
As listed in the register: ZYKADIA
150 mg · capsule
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ceritinib
- Made by
- Novartis Pharmaceuticals Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (ZYKADIA). It describes the substance, not this exact product.
Ceritinib is a kinase inhibitor.
Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinically relevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-12-15
Safety of the active substance
From the US prescribing label for the same active substance (ZYKADIA). It describes the substance, not this exact product.
The most common adverse reactions (≥ 25% incidence) were diarrhea, nausea, vomiting, fatigue, abdominal pain, decreased appetite, and weight loss.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Novartis Pharmaceuticals Canada Inc |
|---|---|
| Active substance | Ceritinib |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 150 mg |
| Form | capsule |
| Classification | L01ED02 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02436779 |
| DPD drug code | 92108 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.